We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+23.73%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.85B
AUM Growth
+$953M
(+50%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
19.37%
Top 10 Holdings %
Top 10 Hldgs %
57.93%
Holding
41
New
6
Increased
9
Reduced
8
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$116M |
| 2 |
GSK
GSK
|
+$112M |
| 3 |
Tenet Healthcare
THC
|
+$64.5M |
| 4 |
Biogen
BIIB
|
+$51.6M |
| 5 |
Universal Health Services
UHS
|
+$31.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$42.4M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$41.3M |
| 3 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$32.9M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$30.4M |
| 5 |
Atara Biotherapeutics
ATRA
|
+$18.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.16% |
| 2 | Technology | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDUS
26
DELISTED
Radius Health, Inc.
RDUS
| $37.1M | 1.3% |
2,075,000
| – | – |
|
|
BLUE
27
DELISTED
bluebird bio
BLUE
| $34.6M | 1.21% |
61,760
-23,160
| -27% | -$14.7M |
|
28
OraSure Technologies
OSUR
$279M
| $34.4M | 1.21% |
3,250,000
+500,000
| +18% | +$6.56M |
|
29
Puma Biotechnology
PBYI
$454M
| $26.2M | 0.92% |
2,555,000
| – | – |
|
|
DRNA
30
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $11.6M | 0.41% |
525,000
| – | – |
|
31
AngioDynamics
ANGO
$649M
| $8.28M | 0.29% |
540,362
+519,486
| +2,488% | +$6.59M |
|
|
CBIO
32
Crescent Biopharma
CBIO
$626M
| $8.27M | 0.29% |
22,000
-3,000
| -12% | -$1.05M |
|
|
33
Atara Biotherapeutics
ATRA
$76.1M
| – | – |
-56,000
| Closed | -$18.1M |
|
|
34
BioMarin Pharmaceuticals
BMRN
$12.3B
| – | – |
-400,000
| Closed | -$30.4M |
|
|
35
Cigna
CI
$74.6B
| – | – |
-250,000
| Closed | -$42.4M |
|
36
Immunovant
IMVT
$8.25B
| – | – |
-438,800
| Closed | -$15.4M |
|
37
Sutro Biopharma
STRO
$421M
| – | – |
-60,000
| Closed | -$6.03M |
|
38
Vir Biotechnology
VIR
$1.49B
| – | – |
-16,464
| Closed | -$565K |
|
|
GBT
39
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-50,000
| Closed | -$2.76M |
|
|
AMAG
40
DELISTED
AMAG Pharmaceuticals
AMAG
| – | – |
-4,390,000
| Closed | -$41.3M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Camber Capital Management held 41 positions worth $2.85B, up 50% from $1.9B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Camber Capital Management deployed $552M of net new capital in Q4 2020, opening 6 new positions and adding to 9 existing holdings. Its largest new stake was Walgreens Boots Alliance: 3,000,000 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Change Healthcare Inc. Common Stock, an estimated $32.9M trimmed.
- Camber Capital Management's largest Q4 2020 buy was Walgreens Boots Alliance: 3,000,000 shares worth $120M.
- Camber Capital Management added most to GSK in Q4 2020, an estimated $112M increase.
- Camber Capital Management's biggest Q4 2020 reduction was Change Healthcare Inc. Common Stock, cutting an estimated $32.9M.
- Camber Capital Management fully exited Cigna in Q4 2020, selling an estimated $42.4M.
- Camber Capital Management's ten largest holdings make up 58% of its $2.85B portfolio in Q4 2020.
- Camber Capital Management opened 6 new positions and closed 9 in Q4 2020.
- Camber Capital Management's portfolio value rose 50% quarter-over-quarter to $2.85B.
Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.